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Abstract
Gastric cancer with Laurèn diffuse types is increasing in the West. The raising trend is more evident when considering 
signet ring cells (SRC) histology. However, to control the biologic potential of this GC subtype, some hypotheses of tai-
lored therapeutic strategies for SRC cancers have been made. A review of the literature was performed using the key words 
“signet ring cells” AND “gastric cancer”. Results of literature review were descriptively reported. Endoscopic submucosal 
dissection (ESD), according to the Japanese extended criteria, could be a therapeutic option for early SRC tumours. How-
ever, according to the evidences from more recent studies, indications for ESD to these tumours types should be carefully 
considered. Concerning the optimal surgical treatment, considering the high lymphotropism and infiltrating behaviour of 
SRC histotype, the extension of gastric resection should be wider than for intestinal type cancer and laparoscopic surgery 
should be performed carefully. Moreover, D3 lymphadenectomy could provide a benefit in diffuse-type and SRC histology. 
The role of surgery in gastric cancer with peritoneal carcinomatosis is still debated and studies on this topic should stratify 
the good results according to GC histotype. Finally, despite the evidences of chemoresistance in SRC, ongoing randomized 
trials suggest that multimodal therapy could be the best treatment. Based on the assumption that SRC tumours have specific 
features, they deserve a specific multimodal treatment. However, a preliminary step to generate strong evidences in this field 
is the standardization of terminology used to define signet ring cells carcinoma.
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Introduction
Gastric cancer (GC) is still one of the major causes of can-
cer-related death worldwide [1]. Recent epidemiological 
data show a changing in trends of GC histopathological sub-
types. Specifically, a declining incidence of distal intestinal 
tumours has been reported, while the number of proximal 
intestinal cancers and Laurèn diffuse types is increasing. 
The raising trend is even more evident when considering 
tumours with signet ring cells (SRC) histology, according 
to the WHO classification [2–4].
SRCs tumours have an aggressive behaviour. Indeed, 
higher rate of peritoneal carcinomatosis, lymph node inva-
sion and a lower rate of curative resections are reported 
for SRC compared to non-SRC tumours [5]. Despite these 
observations, the prognostic role of SRC histology is con-
troversial [5, 6]. Some studies conclude that SRC type is an 
unfavourable prognostic factor [5], whereas other studies did 
not confirm this impact [6]. Other authors, when stratifying 
survival by tumour stage, report a paradoxical better sur-
vival in SRC compared to non-SRC tumours at early stages, 
suggesting that driver mutations controlling the metastatic 
potential of SRC may occur later in process of carcinogen-
esis [7, 8].
However, to control the biologic potential of this GC sub-
type, some hypotheses of tailored therapeutic strategies for 
SRC cancers have been made. The present overview aims 
to report the existing evidences supporting the need of dedi-
cated treatment options for GC with SRC histology.
The article is part of topical collection on Gastric Cancer Surgery.
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Materials and methods
A review of the literature was performed by searching in 
PubMed for papers using the key words “signet ring cells” 
and “gastric cancer”. Only studies in English language 
focused on treatment of SRC gastric cancer were considered. 
Results of literature review were descriptively reported.
Evidences of tailored treatment in SRC
Endoscopic resection
According to the extended criteria proposed by Gotoda 
et al. [9], the endoscopic submucosal dissection (ESD) 
could be a possible therapeutic option also for some cases 
of early gastric cancer with undifferentiated histology 
including SRC tumours. However, although many retro-
spective studies from the East, showed good long-term 
results after curative endoscopic resection following 
extended criteria [10], many doubts persist regarding the 
safety of such therapeutic approach specifically in case of 
neoplasms with undifferentiated histotype [11].
Currently, there are no results of dedicated prospective 
studies. In addition, cases of lymph node metastasis have 
been reported in tumours with undifferentiated histotype 
that could be removed endoscopically according to the 
extended criteria. Chung et al. [12] in a surgical series of 
1721 patients, reported 1.15% (3/261 patients) of lymph 
node metastasis in tumours with undifferentiated histotype, 
less than 2 cm with no ulceration. Moreover, Hirasawa et al. 
[13] reported a case of gastric adenocarcinoma with undif-
ferentiated histotype radically removed by ESD confirming 
the conventional histology of 13-mm intramucosal lesion, 
without radiologically evident perigastric lesion ulceration, 
which was then positive for lymph node metastasis.
A further issue in generalizing the indications from 
Eastern studies to the West is the different pathological 
classification routinely used for gastric cancer. Indeed, in 
the above-mentioned studies [9, 10], proving the safety 
of endoscopic resection for early tumours according to 
expanded indications; the Japanese pathological classifi-
cation of GC has been used. However, there is no perfect 
correspondence between the Laurèn [14] and WHO [15] 
classifications that are commonly adopted in the West and 
the Japanese classification [16]. Indeed, undifferentiated 
histotype of the Japanese classification comprises both 
the Laurèn diffuse, including WHO SRC tumours, and the 
poorly differentiated intestinal Laurèn types.
Of note, Western authors reported in early gastric can-
cer a rate of nodal metastasis ranging between 5 and 21% 
[17, 18] that is higher of those observed in Eastern series. 
This may due to differences in tumour biology, specifi-
cally to a different proportion of tumours with Laurèn 
diffuse and SRC histology. As such, possible indications 
for endoscopic resection to these tumours types should be 
carefully considered. This is also suggested by more recent 
data specifically focused on early gastric cancer with SRC 
histotype in which a higher rate of nodal involvement com-
pared to other histotypes has been observed [19–26].
In conclusion, more studies are needed to assess the onco-
logical safety of endoscopic resection for SRC tumours after 
a standardized histological definition between Eastern and 
Western studies.
Surgical treatment
The debate on optimal surgical treatment takes into account 
both the issue of resection margins and the extension of 
lymphadenectomy.
With regard the resection margins, Piessen et al. demon-
strated that SRC tumours have lower R0 resection rate due to 
their infiltrating behaviour leading to more positive vertical 
margins despite more extensive surgery [5]. According to 
these evidences, the extension of gastric resection should be 
wider than for intestinal type cancer. If the Italian guidelines 
consider appropriate a proximal margin of 5 cm [27], the 
German’s suggest even 8 cm as desired margin [28]. Addi-
tionally, laparoscopic surgery should be performed carefully 
in advanced gastric cancer with diffuse type as it is related 
to a higher rate of positive surgical margin compared to 
intestinal type tumours. Indeed, Kelly et al. showed a 10% 
of R1 resection after laparoscopy compared to 1% of open 
approach, among these R1, 75% were SRC tumours [29].
Another characteristic of diffuse tumours is the lym-
photropism and the greater propensity to metastatize to 
third level nodes as compared to intestinal tumours [30]. 
Nowadays, according to Eastern and Western guidelines [11, 
27, 28], the standard of care for locally advanced GC is D2 
lymphadenectomy. But, some studies tried to evaluate if D3 
lymphadenectomy could provide a benefit in subgroups of 
GC at high risk of nodal metastases, namely the tumours 
with diffuse-type and SRC histology. There is evidence that 
D3 lymphadenectomy is associated with a lower risk of 
locoregional recurrence in tumours with diffuse histology 
compared to D2 [31].
SRC tumours are also characterized by a higher preva-
lence of synchronous or metachronous peritoneal carcino-
matosis. As reported by Kim et al. [32] unsuspected perito-
neal carcinomatosis is significantly more frequent in SRC 
compared to non-SRC cases (18.6% vs. 6.0%, p = 0.013) 
leading to poorer prognosis. Based on these observations, 
some authors suggest to better evaluate the role of Hyper-
thermic intraperitoneal chemotherapy (HIPEC) in the 
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tailored treatment of SRC gastric tumours both in prophy-
lactic and therapeutic settings. Desiderio et al. showed a 
better long-term survival rate, in locally advanced (cT3/4) 
tumours with negative cytology underwent to prophylactic 
HIPEC [33]. More debated is the therapeutic use of HIPEC. 
In patients with positive peritoneal cytology at diagnosis, 
when converted to a negative cytology by neoadjuvant 
chemotherapy, surgery does not improve survival [34]. But, 
Badgwell et al. documented an improved overall survival 
(median OS of 30.2 months) for patients with gastric cancer 
metastasis limited to the peritoneum who underwent multi-
modality treatment with chemotherapy and HIPEC repeated 
until obtaining negative cytology, and successively under-
gone to surgery [35]. Moreover, the role of surgery in gastric 
cancer with peritoneal carcinomatosis is still debated. In a 
recent Korean study, Kim analysed the results of conversion 
surgery in a series of patients with peritoneal seeding. They 
interestingly, found that the median survival time of patients 
underwent curative conversion surgery was 37 months, and 
the 3-year survival rate was 50%. The differences between 
the studied groups were statistically significant [36]. Stud-
ies on this topic should stratify the results according to GC 
histotype.
Multimodal therapy
Since 2005 when the results of the MAGIC study were 
published [37], perioperative chemotherapy (PCT) based 
on epirubicin–cisplatinum-5-fluorouracil (ECF) was rec-
ommended for locally advanced gastric cancer. However, 
there are some evidences of chemoresistance in SRC gastric 
tumours. Heger et al. analysed response and prognosis after 
neoadjuvant treatment in 723 locally advanced esophago-
gastric adenocarcinomas. They found that SRC carcinoma 
was associated with more aggressive behaviour and lower 
survival rate. However, although response to neoadjuvant 
chemotherapy is rare in SRC, it is associated with improved 
outcome [38].
Messager et al. showed that PCT does not provide any 
survival advantage in SRC due to an absence of both cyto-
toxic and cytostatic effects, in these cases delay in definitive 
surgery may favour tumour progression [39]. Piessen et al. 
in a randomised phase II/III trial hypothesise that a policy 
of primary surgery followed by adjuvant chemotherapy will 
improve overall survival compared to a standard periopera-
tive chemotherapeutic strategy [40]; in this case, however, 
we have to face to the difficulty to accomplish an adjuvant 
therapy after a major surgery.
Preliminary data of Al Batran et al.’s phase III trial show 
promising results by the administration of FLOT scheme 
as perioperative chemotherapy in GC with a significantly 
increased proportion of patients achieving pathological com-
plete regression compared with ECF/ECX [41]. This effect 
is especially evident in intestinal type tumours but Al Batran 
et al.’s preliminary data showed that also SRC tumours could 
have a good response. However, also in the field of multi-
modal treatment SRC needs special considerations in the 
choice of best therapeutic option.
Conclusions
Gastric cancer with SRC histology is increasing in the West 
[4]. Based on the assumption that SRC tumours have spe-
cific features, they deserve a specific multimodal treatment. 
The evidences reported in the present overview suggest that 
indications for endoscopic resection, the extent of surgery 
and the type of multimodal treatment should be tailored on 
the characteristics of SRC tumours. However, a preliminary 
step to generate strong evidences in this field is the stand-
ardization of terminology used to define signet ring cells 
carcinoma. Indeed, currently the terms “diffuse type” cancer, 
“Poorly Cohesive” and “Signet Ring Cell” gastric carcino-
mas, according to the Laurén classification and 2010 WHO 
classification, respectively, or also “linitis plastica” are used 
indiscriminately. This represents a hot topic of clinico-bio-
logical research in gastric cancer.
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